Human induced pluripotent stem cells (hiPSCs) can theoretically yield limitless supplies of cells fated to any cell type that comprise the human organism, making them a new tool by which to potentially overcome caveats in current biomedical research. In vitro derivation of central nervous system (CNS) cell types has the potential to provide material for drug discovery and validation, safety and toxicity assays, cell replacement therapy and the elucidation of previously unknown disease mechanisms. However, current two-dimensional (2D) CNS differentiation protocols do not faithfully recapitulate the spatial organization of heterogeneous tissue, nor the cell-cell interactions, cell-extracellular matrix interactions, or specific physiological functions generated within complex tissue such as the brain. In an effort to overcome 2D protocol limitations, there have been advancements in deriving highly complicated 3D neural organoid structures. Herein we provide a synopsis of the derivation and application of neural organoids and discuss recent advancements and remaining challenges on the full potential of this novel technological platform.
Introduction
Recapitulating the complexity of human development under in vitro conditions has been the central tenet of the developmental stem cell biology field from its inception. Current progress towards this goal has provided new platforms for biomedical applications such as disease phenotyping, drug discovery and validation, and the elucidation of unknown disease mechanisms, whilst in addition providing a potential source of material for cell replacement therapy. At the core of this tenet is the leveraging of two fundamental stem cell properties; their ability to divide indefinitely and theoretically be specified to all cell fates of the human. Since the initial description of the culture conditions required for the derivation of both human embryonic stem cells (ESCs) (Thomson et al., 1998) and induced pluripotent stem cells (hiPSCs) (Takahashi et al., 2007) there has been a multitude of publications defining the conditions required to derive the cellular subtypes of the different germ layers.
Many early differentiation strategies mimicked early developmental biology spatial arrangement by transitioning through a spheroid structure known as an embryoid body (EB). Within EBs, spontaneous differentiation toward the three germ layers occurs and subsequent enrichment of cell types of interest can be achieved by the use of specific basal media and protein or small molecule additives. With time, a number of reports suggested that monolayer differentiation protocols were a more rapid and efficient alternative because defined soluble morphogens such as growth factors and extracellular microenvironment substrates could be more precisely controlled (Ying and Smith, 2003) . Furthermore, these monolayer approaches provided a platform by which precise regional specification of PSCs could be induced by modulating rostrocaudal and dorsoventral developmental cues elucidated from developmental neurobiology studies (Chambers et al., 2009; Espuny-Camacho et al., 2013; Fasano et al., 2010; Kriks et al., 2011; Lee et al., 2010; Maroof et al., 2013; Perrier et al., 2004; Nicholas et al., 2013) .
There has recently been a resurgence in harnessing the selforganizational and specification capacities of non-adherent culture systems to derive neural cytoarchitectures that are more analogous to the three-dimensionality (3D) of the human brain (well reviewed in Kelava and Lancaster, 2016; Yin et al., 2016) . Although 3D organization is stochastic and undirected, such structures should allow cellular phenotyping of disease traits not applicable to modeling in animals or in 2D, particularly as neural organoids begin to incorporate a growing number of physiologically relevant cell types. Moreover, from a developmental biology perspective, neural organoids are an invaluable resource to study minutiae of human brain development, as access to human brain tissue is extremely scarce.
Current methods for derivation of neural organoids
Complex in vitro neural cytoarchitectures were first demonstrated using the serum-free floating culture of EB-like aggregates with quick re-aggregation (SFEBq) technique, where presumptive regions such as cerebral cortex (Danjo et al., 2011; Eiraku et al., 2008) and pituitary gland (Suga et al., 2011) self-organized from mouse ESCs. Translation into human development neurobiology was seen shortly after, when Mariani et al., showed that repurposing the SEFBq technique for human ESCs resulted in selforganized structures that by gross cytoarchitecture, transcript and protein expression resembled the developing human cerebral cortex (Mariani et al., 2012) (Fig. 1) . These structures possessed layer specific complexity, and both major neurotransmitters neuronal subtypes of the cortex, glutamatergic and g-aminobutyric acid (GABA)-ergic. While the authors also found evidence for early synapse formation, they did not report any functional data in this early study. This was a seminal paper, which demonstrated for the first time that human ESCs could generate structures analogous to the developing brain in vitro.
Using a novel spinning bioreactor approach, Lancaster et al., reported that heterogeneous cerebral organoids containing numerous, but discrete brain regions per organoid could be generated (Lancaster et al., 2013) . The diverse array of structures included presumptive hippocampus, choroid plexus, dorsal cortex ventral telencephalon and retina (Lancaster et al., 2013) (Fig. 2) . This protocol relied solely on the capacity of EBs to self-organize and specify, as no neural induction cues or morphogenic signals were used, owing at least in part to the large volumes associated with a bioreactor strategy (Lancaster and Knoblich, 2014) . While this resulted in many EBs failing to commit to the neural lineage and a relatively low-efficiency protocol, the combination of embedding the growing cerebral organoids in Matrigel droplets together with the use of a spinning bioreactor resulted in cerebral organoids that could grow up to~4 mm, staggeringly approaching the size of a E12.5 mouse brain (Paş ca et al., 2015) . Additionally, this novel strategy avoided the lack of oxygen and nutrient absorption, a persistent problem reported in other static 3D tissue constructs (Lancaster and Knoblich, 2014; McMurtrey, 2016) .
However, the aforementioned protocols are costly due to the use of expensive commercial plates, large bioreactor volumes and the requirement for substantial manual manipulation of single cell intermediates in 96 well plates. In an effort to address such drawbacks, a recent paper demonstrated that cerebral organoids, or human cortical spheroids (hCS) (Paş ca et al., 2015) , could be generated by simply dissociating intact hiPSC colonies from adherent hiPSC cultures. This protocol utilized bone morphogenetic protein (BMP) and transforming growth factor beta (TGFB) signaling pathway inhibitors to induce robust and rapid neural induction (Fig. 3A) , but did not use cell specification factors, again relying on the self-organizational and speciation capacity of the EBs following neural induction (Paş ca et al., 2015) . Remarkably, although this protocol did not employ the use of bioreactors or Matrigel droplets, it still yielded structures in the range of~4 mm (Fig. 3D) . The cytoarchitecture of the hCS resembled that of the developing human cortex, with cells expressing markers of both superficial and deep layer cortical makers (Paş ca et al., 2015) . Although, the authors reported that long-term culturing of hCS generated non-reactive astrocytes ( Fig. 3B and C) , a major cell type of the CNS and one that has been difficult to obtain by current in vitro methods, the hCS did not produce GABAergic neurons (Paş ca et al., 2015) , illustrating that different methodologies result in different cell compositions in maturing organoids.
To further build the complexity of cerebral organoids, organoids can also be engineered by mixing defined populations of multiple CNS cell types. Neural progenitor cells (NPCs), mesenchymal stem cells, endothelial cells and microglia/macrophage progenitors were derived independently from hESCs, mixed at different time points to mimic in vivo development and allowed to organize on hydrogel into a 3D structure known as a "neural construct" (Schwartz et al., 2015) . Surprisingly, the hESC-derived endothelial cell and mesenchymal stem cells, added after the NPCs had self-assembled into multilayered neural and glial populations, organized into microstructures indicative of capillary networks and appeared to vascularize the neuronal layers (Schwartz et al., 2015) . Moreover, the microglia/macrophage precursors, which were added after this initial vascular network assembly, attained both amoeboid and ramified morphologies, incorporated into, and dispersed throughout the neuronal constructs and associated with the endothelial tubules (Schwartz et al., 2015) . Such "neural constructs" move away from the "neurocentric view" that has dominated in vitro neuroscience and demonstrate that it is now possible to engineer organoids that are complex multicellular integrated systems.
By combining organoid methodologies with neural patterning protocols developed for monolayer differentiation, it now seems possible to specify a variety of organoid fates. For example, modulating Wingless-type MMTV integration site family (WNT) and BMP signaling pathways dorsalizes the developing organoid into choroid plexus, the most dorsomedial portion of the telencephalon; long-term culture yields mature granule and pyramidal neurons expressing hippocampal fate markers (Sakaguchi et al., 2015) . Although a variety of brain region-specific organoid protocols should be possible, in order to reduce the costs associated with including an increasing number of complex patterning factors, it is necessary to conduct organoid differentiations in ever-smaller volumes. Now, in the biggest advance to date, the scalability of organoid generation via bioreactors has been dramatically improved through the application of computer-aided software design and 3D printing technologies. Following many prototype iterations to optimize designs that sustained various sized organoids and prevented tissue shearing under moderate spinning speed, as well as aggregation at the center of the well, SpinU was created ( Fig. 4A) (Qian et al., 2016) . This radically newly designed, miniaturized spinning bioreactor requires only minimal media; it fits into a conventional 12 well plate and can be built in a modular stackable version (Fig. 4B ) permitting large-scale parallel experimental design at both reduced cost and reduced incubator footprint. Spinning bioreactor requires only minimal media; it fits into a conventional 12 well plate and can be built in a modular stackable version (Fig. 4B) permitt.
Moving forward, the field will require neural organoid derivation protocols more amenable to scalability, automation and throughput. In contrast to the manipulation of adherent colonies or single cells outlined in the aforementioned proof-of-concept reports, Rigamonti et al., demonstrate that by beginning with 3D spheres of hESCs and hiPSCs, rather than adherent colonies, EBs can be generated simply by changing the growth medium (Rigamonti et al., 2016) . Moreover, the EBs they describe are more uniform in both size and shape, do not require transition through a cell intermediate or matrigel droplet manipulation, and can be directed to either functionally mature cortical or motor neuron fates by changing the growth factor additives (Rigamonti et al., 2016) . The authors conclude that this protocol is capable of yielding subtype specific populations of neurons in a highly reproducible fashion with minimal experiment-to-experiment variation.
To ascertain the extent to which hiPSC-derived 3D cerebral tissues recapitulate gene expression and cell type composition of the developing human cortex, single-cell RNA-sequencing compared cerebral organoids and fetal neocortex. Covariate network analysis revealed progenitor-to-neuron transcriptional programs in cerebral organoids, similar to that of the developing cortex, and diverse cell types of both neuronal and mesenchymal lineages (Camp et al., 2015) .
These reports demonstrate that neural organoids represent an accurate approximation of the developing fetal cortex, midbrain, hippocampus, and hypothalamus. Aside from recapitulating the intricacies of human brain development for developmental biology studies, neural organoids provide a platform to begin elucidating disease mechanisms that may only be apparent in higher order neural cytoarchitectures. Moreover, they may be appropriate for modeling diseases specific to human neural function, not applicable to modeling in rodents.
Application of CNS organoids
Organoid methodologies are uniquely suited for phenotypic and mechanistic studies of hiPSC-based models of a number of neurodevelopmental disorders, particularly those characterized by perturbations in neural patterning during fetal development. Below we discuss a number of recent reports applying cerebral organoids to the understanding of microcephaly, macrocephaly, autism spectrum disorders and Zika virus pathogenicity.
Cerebral organoids derived from a patient with a truncating mutation in CDK5RAP2 and afflicted with severe microcephaly served as the first demonstration that this system was applicable for disease modeling; patient-derived organoids exhibited premature neural differentiation at the expense of early neural progenitors, disrupted radial glia spindle orientation, reduced total neural tissue and increased neuronal outgrowth (Lancaster et al., 2013) . Moreover, the authors demonstrated that CDK5RAP2 levels were in part responsible for the observed hypoplasia, as RNA interference (RNAi) in control organoids was able to phenocopy radial glial spindle disruption, while CDK5RAP2 overexpression, although toxic, was able to partially rescue the phenotype (Lancaster et al., 2013) . More recently, when cerebral organoids derived from patients with idiopathic autism (with an increased head/brain size) were compared with their non-affected fathers, transcript dysregulation was consistent with observations of abnormal cell proliferation and an over-production of inhibitory neurons (Mariani et al., 2015) ; supporting the long-held hypothesis that excitatory/inhibitory balance may exist in the autistic brain (Rubenstein, 2010) . The investigators were able to establish that one of the overexpressed transcripts, FOXG1, correlated with symptom severity (Mariani et al., 2015) in their patient cohort; when RNAi was used to reduce FOXG1 levels in cerebral organoids differentiated from one of the proband-derived hiPSC lines, the overproduction of GABAergic inhibitory neurons was attenuated (Mariani et al., 2015) . Together, these two studies demonstrate that organoids can be useful for phenotypic and mechanistic insights into both simple and complex genetic neurodevelopmental disorders.
hPSC-derived cell types are becoming increasingly utilized as a source of material for microphysiological systems, or "organs-on-achip", demonstrating that they are well positioned to serve as an improved method to asses drug efficacy and safety (Fabre et al., 2014; Judson et al., 2014; Shinde et al., 2016; Sirenko et al., 2016) . Focusing on the ability of organoids to refine toxicology testing, neural constructs engineered from multiple cell types were treated with a set of compounds, comprising both known neurotoxic compounds and control chemicals; RNA-sequencing combined with machine learning was able to accurately predict neurotoxic compounds in 90% of tests (Schwartz et al., 2015) . Moving forward, organoid-based approaches may serve as a useful (and potentially high throughput) preclinical assay to evaluate the toxicity of new hit compounds identified in pharmaceutical drug screening in a more physiologically relevant manner.
Three recent papers demonstrated the potential of organoidbased disease modeling in ascertaining how Zika virus (ZIKV) results in microcephaly (Mlakar et al., 2016) . Miniaturized spinning bioreactors, described above, were used to generate forebrain organoid tissue that was subsequently transduced with both African and Asian ZIKV (Qian et al., 2016) . Neural progenitor cells within the organoid were preferentially infected, which lead to cell death and reduced proliferation resulting in decreased cerebral organoid volume reminiscent of microcephaly (Qian et al., 2016) (Fig. 4D ). Such observations were confirmed when an independent group from Brazil infected both organoids and neurospheres with ZIKV (Garcez et al., 2016) . To investigate how ZIKV infection results in microcephaly at a molecular level, RNAseq was conducted on Toll-like-Receptor 3 (TLR3) activated organoids (Dang et al., 2016) as ZIKV and other flaviviruses have been demonstrated to activate TLR3 (Hamel et al., 2015; Tsai et al., 2009 ). Pathway analysis of gene expression changes suggested that ZIKV perturbs a TLR3-regulated network controlling neurogenesis and apoptotic pathways (Dang et al., 2016) . In an effort to validate their hypothesized link between ZIKV-mediated TLR3 activation and dysregulation of neurogenesis and apoptosis, organoids were treated with TLR3 competitive inhibitor in the presences of ZIKV. Although the authors reported that TLR3 competitive inhibitor attenuated the severe ZIKV-mediated apoptosis and organoid shrinkage seen in ZIKV-only-treated organoids, substantial cell death was still observed (Dang et al., 2016) . The rapid publication of these organoid-based studies of ZIKV demonstrating a causal link between infection and aberrant neurodevelopmental processes, in fact, preceded comparable studies in rodents and non-human primates, indicating the rapid and broad utility of this platform for studies of complex neurodevelopmental diseases.
Future perspectives and predicted caveats
Cerebral organoids exhibit a remarkable level of selforganization and specification relative to what can be achieved in 2D monolayer cultures; however, many hurdles remain before the full potential of this technologically advanced platform can be realized. For example, we envisage that the field must address several issues, including but not limited to the developmental stage of organoids, standardization and reproducibility of protocols, region-specific organoid patterning, addressing diffusion-imposed limitations of organoid size, providing surrounding supportive tissue found in the brain, integrating functional non-neuronal cell types within organoids and in situ analysis of neural connectivity and function within the organoids.
It is becoming increasingly critical to consider the time point at which assays should be conducted using neural organoids. To date, the most developmentally advanced neural organoids demonstrate a transcriptomic signature that correlates with later 2nd trimester and/or early 3rd trimester human fetal brain tissue (Mariani et al., 2015; Paş ca et al., 2015; Qian et al., 2016) , only marginally more advanced than monolayer differentiations (Brennand et al., 2014; Mariani et al., 2012; Nicholas et al., 2013) indicating that these platforms may all be best suited for the study of genetic predisposition to disease. For the modeling and subsequent highthroughput drug screening of neurodevelopmental diseases, this hopefully represents an acceptable developmental time point for use, however the question of whether this will prove to be suitable for studies of neurodegenerative diseases remains to be seen. It is worth noting that a recent publication demonstrated the derivation of midbrain organoids that produced neuromelanin-like granules, structurally similar to those in the human substantia nigra (Jo et al., 2016) , an observation not reported in 2D differentiated cultures (Jo et al., 2016; Kriks et al., 2011) , suggesting they attain a more "midbrain-like" approximation, and thus potentially more suitable for the cellular modeling of Parkinson's disease.
Until very recently, except for neural induction cues, most cerebral organoid protocols did not utilize patterning of specification cues. As occurred with earlier monolayer differentiation protocols, defining the conditions required for the derivation of specific brain regions will be a critical component of future organoid protocols and will likely improve the sensitivity of subsequent disease modeling studies. In parallel, the addition of patterning factors should specify the differentiation of an expanded diversity of neuronal cell subtypes within patterned brain regions, as well as potentially providing a mechanism for controlling high order tissue organization and avoiding stochastic growth patterns (Drasdo et al., 2007) . As organoids grow in size during the differentiation process, the lack of diffusion of exogenous growth factor proteins or small molecule mimetics may present an obstacle for cell fate specification; the recent engineering of the mini-bioreactor has somewhat addressed this caveat (Qian et al., 2016) . Moreover, owing to the lack of surrounding supportive tissue and axial cues, cerebral organoids do not develop into the shape and structure of the brain as in vivo. A conceivable solution for these issues may come from the advancements being made in field of bioengineering and 3D printing; for example, precise spatial-temporal control of differentiation could be achieved by using scaffolds functionalized with cell patterning proteins or peptides (Callahan et al., 2013; Scapin et al., 2015) or by mimicking endogenous developmental signaling gradients using control-released nanoparticles (Formiga et al., 2010; Moioli et al., 2006) . In parallel, the derivation and/or integration of non-neuronal cell types such as astrocytes, microglia, meningeal cells and cells of the vasculature will also need to be addressed. Non-reactive astrocytes have been reported from the long-term culturing of cerebral organoids (Paş ca et al., 2015) or by using the mini-bioreactor approach (Qian et al., 2016) , a critical advance given the increasing role that astrocytes are ascribed in the formation of synapses and disease initiation/progression (Clarke and Barres, 2013; Molofsky et al., 2012) . This is also true for microglia, however due to the developmental origin of microglia outside of the CNS (Ginhoux et al., 2015) , the integration of microglia or their precursors (Schwartz et al., 2015) to pre-existing cerebral organoids remains a challenge. Establishing vasculature, perhaps in concert with microfluidic systems similar to "organs-on-a-chip" (van Duinen et al., 2015) may provide a way to deliver non-CNS cell types, however it remains to be established whether current selforganized vasculature within organoids (Schwartz et al., 2015) is functional.
The application of neural organoids for cellular phenotyping and/or high-throughput screening will be dependent upon robust and reproducible standardized protocols for generating homogeneous populations of neural organoids at large scale. To date, no systematic examination of organoid-to-organoid variability has been undertaken. Variability during the differentiation of hPSCs can be attributed to a multitude of sources, such as different hiPSC clones from donors (Vitale et al., 2012) , the donor's genetic (Rouhani et al., 2014) and epigenetic (Nishizawa et al., 2016) background, between differentiation batches due to growth factor and substrate lots and between cells cultured within a single well. As an example, the later has been described to have an affect on cell type maturation (Hochbaum et al., 2014; Shcheglovitov et al., 2013) , and may become particularly important when considering the heterogeneity of cell types expressed within presumptive cortical layers of forebrain organoids, as such a different may be interpreted as a phenotypic difference or "screening hit". Thus, it is not clear whether current protocols generate organoids with fundamentally identical cell compositions from organoid-to-organoid or batch-tobatch. Although Rigamonti et al., argue that starting with 3D hPSC spheres generates neurons of distinct phenotypes in "a highly reproducible manner, with minimal experiment-to-experiment variation" (Rigamonti et al., 2016) , their study only focused on well characterized hPSC lines and thus it remains to be seen how this and other protocols will scale across large cohorts with multiple clones.
Current phenotypic analyses fail to exploit the 3D architecture of organoids, and so may fail to detect disease phenotypes that arise from improper tissue level organization or large-scale connectivity. To date, assays of neural organoid connectivity and neuronal activity have not typically been performed in situ; electrophysiology, calcium imaging and immunofluorescence techniques are generally performed in either slice culture or using dissociated and re-plated organoids (Mariani et al., 2015; Paş ca et al., 2015; Qian et al., 2016) . Combining advanced optical techniques, such as two-photon microscopy (Truong et al., 2011) and light-sheet microscopy (Ahrens et al., 2013 ) with approaches such as optical clearing for immunofluorescence analysis (Azaripour et al., 2016; Chung and Deisseroth, 2013; Renier et al., 2014) will provide a level of analysis in whole intact 3D neural organoids as recently demonstrated (Rigamonti et al., 2016) . Moreover, organoid analyses using advanced genetically encoded indicators (Hochbaum et al., 2014) or reporter cell lines driven by cell type specific promoters (Shcheglovitov et al., 2013) , together with in situ gene expression analysis (Lee et al., 2015) and connectivity mapping (Cai et al., 2013; Markram et al., 2015) will also greatly benefit phenotyping. Altogether, as neural organoid generation becomes more uniform within and between differentiations, and in situ functional analysis is applied, we expect that the organoid platform will become widely used for cell-based models of an array of neurodevelopmental and neurodegenerative disorders.
Conclusion
Although a novel and still evolving approach, cerebral organoids provide a substantially more sophisticated in vitro tool than what has been possible with the use of 2D monolayer neuronal cultures. Already, hiPSC-derived cerebral organoids have provided novel insights into disease processes contributing to microcephaly-and macrocephaly-associated neurodevelopmental disorders. As the field addresses key limitations arising from the variability intrinsic to current protocols, develops means to integrate non-neuronal scaffolds and cell types and establishes in situ analysis of neural connectivity and function within the organoids, we predict that organoids will continue to facilitate complex and physiologicallyrelevant investigations that cannot be conducted in model animals or available human tissue.
